Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Pathophysiology ; (12): 119-123, 2015.
Artigo em Chinês | WPRIM | ID: wpr-474660

RESUMO

AIM:To investigate the role of phospholipase C epsilon 1 ( PLCE1 ) in modulating the apoptotic mechanism in lung adenocarcinoma A 549 cells.METHODS:PLCE1 inhibitor U-73122 was used to suppress the expres-sion of PLCE1.The expression of PLCE1 and p53 in A549 cells was evaluated by quantitative real-time PCR and Western blotting.Apoptosis was assessed by flow cytometry .RESULTS:A549 cells expressed high level of PLCE1 and low level of p53.Inhibition of PLCE1 markedly increased the expression of p 53, and increased the apoptosis of A 549 cells.CON-CLUSION:PLCE1 suppresses apoptosis of A549 cells via inhibiting the expression of p53.

2.
Academic Journal of Second Military Medical University ; (12): 708-713, 2014.
Artigo em Chinês | WPRIM | ID: wpr-839173

RESUMO

Objective: To investigate the effects of pirarubicin on proliferation of bladder cancer cells and the related mechanism. Methods: After bladder cancer cell lines T24 and BIU-87 were treated with 0.4, 0.8, 1.6, and 3.2 mg/L pirarubicin for 24, 48, and 72 h, the cell proliferation was detected by MTT. Flow cytometry was used to examine the apoptosis of T24 and BIU-87 cells. qRT-PCR and RT-PCR were used to examine the mRNA expression of phospholipase C ε (PLCε),Bcl-2 in T24 and BIU-87 cell lines; the protein expression of PLCε in pirarubicin-treated cells was determined by Western blotting analysis. Bladder cancer cells were designed as blank group, pirarubicin treatment group, Ad-shPLCε treatment group, and Ad-shPLCε plus pirarubicin treatment group; cell proliferation was observed and protein expression of Bcl-2 was examined and compared between different groups. Results: Pirarubicin showed a dose-and time-dependent inhibitory effect against proliferation of T24 and BIU-87 cell lines. Moreover, pirarubicin promoted cell apoptosis in T24 and BIU-87 cells and suppressed the expression of PLCε and Bcl-2. Pirarubicin treatment group, Ad-shPLCε treatment group, and Ad-shPLCε plus pirarubicin treatment group all had suppressed cell proliferation and Bcl-2 expression, and pirarubicin plus Ad-shPLCε group exhibited significantly stronger inhibitory effects compared with pirarubicin treatment group (P<0.05). Conclusion: Pirarubicin can effectively inhibit cell proliferation of bladder cancer cells, which may be through suppressing the expression of PLCε and Bcl-2.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA